C5 Convertase of the Alternative Pathway of Complement
Open Access
- 1 July 1998
- journal article
- Published by Elsevier BV
- Vol. 273 (27), 16828-16835
- https://doi.org/10.1074/jbc.273.27.16828
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- TRANSGENIC PIGS EXPRESSING HUMAN CD59 AND DECAY-ACCELERATING FACTOR PRODUCE AN INTRINSIC BARRIER TO COMPLEMENT-MEDIATED DAMAGE1Transplantation, 1997
- Complement Activation and Inhibition in Myocardial Ischemia and Reperfusion InjuryAnnual Review of Pharmacology and Toxicology, 1994
- Silica Induced Suppression of the Production of Third and Fifth Components of the Complement System by Human Lung CellsIn VitroImmunopharmacology and Immunotoxicology, 1994
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisScience, 1990
- The effect of FUT-175 (nafamstat mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivoInternational Journal of Immunopharmacology, 1990
- Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.The Journal of Experimental Medicine, 1987
- Human Alveolar Macrophages Synthesize the Functional Alternative Pathway of Complement and Active C5 and C9 in VitroScandinavian Journal of Immunology, 1986
- Third component of human complement: purification from plasma and physicochemical characterizationBiochemistry, 1976
- Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.The Journal of Experimental Medicine, 1976
- THE ROLE OF PROPERDIN IN THE ALTERNATE PATHWAY OF COMPLEMENT ACTIVATIONThe Journal of Experimental Medicine, 1974